Topic Tree
Status | Stage |
---|---|
- 'As required' medication regimens for seriously mentally ill people in hospital
- Acceptance and Commitment Therapy for schizophrenia and related disorders
- Acetophenazine versus chlorpromazine for schizophrenia
- Acetylcholinesterase inhibitors for schizophrenia
- Acetylsalicylic acid (aspirin) for schizophrenia
- Acupuncture for schizophrenia
- Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia
- Advance treatment directives for people with severe mental illness
- Adverse effects of electroconvulsive therapy
- Allopurinol and related drugs for schizophrenia
- Amisulpride for schizophrenia
- Amisulpride versus other atypical antipsychotics for schizophrenia
- Amphetamines for schizophrenia
- Amphetamines versus placebo for schizophrenia
- Animal-assisted therapy for people with serious mental illness
- Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms
- Anticholinergic medication for antipsychotic-induced tardive dyskinesia
- Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia
- Anticholinergics (various) for neuroleptic-induced parkinsonism
- Anticholinergics for neuroleptic-induced acute akathisia
- Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesia
- Anticholinergics versus placebo for neuroleptic-induced parkinsonism
- Antidepressants for people with both schizophrenia and depression
- Antidepressants for the negative symptoms of schizophrenia
- Antiglucocorticoid and related treatments for psychosis
- Antioxidant treatments for schizophrenia
- Antipsychotic combinations for schizophrenia
- Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
- Antipsychotic drug treatment for elderly people with late-onset schizophrenia
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
- Antipsychotic medication for childhood-onset schizophrenia
- Antipsychotic medication for early episode schizophrenia
- Antipsychotic medication for elderly people with schizophrenia
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
- Antipsychotics for antipsychotic-naïve people with psychosisNew
- Antipsychotics for people with persistent negative symptoms of schizophrenia
- Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
- Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)
- Aripiprazole for neuroleptic induced hyperprolactinaemia
- Aripiprazole for schizophrenia
- Aripiprazole versus brexpiprazole for people with schizophrenia
- Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus other atypical antipsychotics for schizophrenia
- Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus placebo for schizophrenia
- Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus typical antipsychotic drugs for schizophrenia
- Aripiprazole versus ziprasidone for schizophrenia
- Art therapy for schizophrenia or schizophrenia-like illnesses
- Asenapine versus other atypical antipsychotics for schizophrenia
- Asenapine versus placebo for schizophrenia
- Atomoxetine for schizophrenia
- Atypical antipsychotics for people with both schizophrenia and depression
- Atypical antipsychotics for psychosis in adolescents
- Avatar Therapy for people with schizophrenia or related disorders
- Ayurvedic medicine for schizophrenia
- Behavioural family interventions versus structural family interventions for people with schizophrenia
- Behavioural interventions for reducing weight gain in schizophrenia
- Benperidol for schizophrenia
- Benzodiazepines for antipsychotic-induced tardive dyskinesia
- Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
- Benzodiazepines for neuroleptic-induced acute akathisia
- Benzodiazepines for psychosis-induced aggression or agitation
- Benzodiazepines for schizophrenia
- Beta-blocker supplementation of standard drug treatment for schizophrenia
- Bifeprunox versus placebo for schizophrenia
- Blonanserin versus risperidone for schizophrenia
- Brexpiprazole versus placebo for people with schizophrenia
- Bromperidol decanoate (depot) for schizophrenia
- Calcium channel blockers for antipsychotic-induced tardive dyskinesia
- Cannabidiol for people with schizophrenia
- Cannabis and schizophrenia
- Carbamazepine for schizophrenia
- Cariprazine versus placebo for schizophrenia
- Celecoxib plus standard care for people with schizophrenia
- Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia
- Cessation of medication for people with schizophrenia already stable on chlorpromazine
- Chinese herbal medicine for schizophrenia
- Chlorpromazine dose for people with schizophrenia
- Chlorpromazine for psychosis induced aggression or agitation
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
- Chlorpromazine versus clotiapine for schizophrenia
- Chlorpromazine versus lithium for people with schizophrenia
- Chlorpromazine versus metiapine for schizophrenia
- Chlorpromazine versus penfluridol for schizophrenia
- Chlorpromazine versus piperacetazine for schizophrenia
- Chlorpromazine versus placebo for schizophrenia
- Chlorpromazine versus reserpine for schizophrenia
- Chlorpromazine versus thiothixene for people with schizophrenia
- Cholinergic medication for antipsychotic-induced tardive dyskinesia
- Clotiapine for acute psychotic illnesses
- Clozapine (generic versus branded) for people with schizophrenia
- Clozapine augmentation for treatment-resistant schizoaffective disorder
- Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
- Clozapine dose for schizophrenia
- Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia
- Clozapine versus olanzapine for people with schizophrenia
- Clozapine versus other atypical antipsychotics for schizophrenia
- Clozapine versus quetiapine for people with schizophrenia
- Clozapine versus risperidone for people with schizophrenia
- Clozapine versus typical neuroleptic medication for schizophrenia
- Cognitive behaviour therapy versus specific pharmacological treatments for schizophrenia
- Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
- Cognitive behavioural therapy (group) for schizophrenia
- Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosisNew
- Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
- Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
- Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
- Cognitive behavioural therapy without medication for schizophreniaNew
- Cognitive rehabilitation for people with schizophrenia and related conditions
- Collaborative care approaches for people with severe mental illness
- Communication skills training for mental health professionals working with people with severe mental illness
- Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality
- Compliance therapy for schizophrenia
- Compulsory community and involuntary outpatient treatment for people with severe mental disorders
- Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders
- Containment strategies for people with serious mental illness
- Crisis intervention for people with severe mental illnesses
- Dance therapy for schizophrenia
- Day centres for severe mental illness
- Day hospital versus admission for acute psychiatric disorders
- Day hospital versus outpatient care for people with schizophrenia
- De-escalation techniques for psychosis-induced aggression or agitation
- Depot fluspirilene for schizophrenia
- Depot haloperidol decanoate for schizophrenia
- Depot perphenazine decanoate and enanthate for schizophrenia
- Depot pipotiazine palmitate and undecylenate for schizophrenia
- Dietary advice for people with schizophrenia
- Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders
- Distraction techniques for schizophrenia
- Drama therapy for schizophrenia or schizophrenia-like illnesses
- Droperidol for psychosis-induced aggression or agitation
- Early intervention for psychosis
- Educational games for mental health professionals
- Electroconvulsive therapy for schizophrenia
- Electroconvulsive therapy for treatment-resistant schizophrenia
- Enhanced crisis planning for serious mental illness
- Estrogen for schizophrenia
- Exercise therapy for schizophrenia
- Family intervention (brief) for schizophrenia
- Family intervention for schizophrenia
- Family-based interventions versus standard care for people with schizophrenia
- First rank symptoms for schizophrenia
- Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
- Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia
- Fluphenazine (dose) for people with schizophrenia
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
- Fluphenazine (oral) versus placebo for schizophrenia
- Fluphenazine decanoate (depot) and enanthate for schizophrenia
- Fluphenazine decanoate (timing of administration) for people with schizophrenia
- Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia
- Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia
- General physical health advice for people with serious mental illness
- Ginkgo biloba versus placebo for schizophrenia
- Glutamatergic drugs for schizophrenia
- Haloperidol (route of administration) for people with schizophrenia
- Haloperidol discontinuation for people with schizophrenia
- Haloperidol dose for the acute phase of schizophrenia
- Haloperidol for long-term aggression in psychosis
- Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
- Haloperidol plus promethazine for psychosis-induced aggression
- Haloperidol versus chlorpromazine for schizophrenia
- Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
- Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia
- Haloperidol versus olanzapine for people with schizophrenia
- Haloperidol versus placebo for schizophrenia
- Haloperidol versus risperidone for schizophrenia
- HIV prevention advice for people with serious mental illness
- Horticultural therapy for schizophrenia
- Humour-based interventions for people with schizophrenia
- Hypnosis for schizophrenia
- Illness management and recovery programme for people with severe mental illness
- Iloperidone versus placebo for schizophrenia
- Implementation of treatment guidelines for specialist mental health care
- Increasing antipsychotic dose for non response in schizophrenia
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
- Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness
- Information and communication technology based prompting for treatment compliance for people with serious mental illness
- Information and communication technology in patient education and support for people with schizophrenia
- Intensive case management for severe mental illness
- Intercessory prayer for the alleviation of ill health
- Intermittent drug techniques for schizophrenia
- Interventions for antipsychotic-induced amenorrhoea
- Interventions for obsessive compulsive symptoms in people with schizophrenia
- Interventions for prodromal stage of psychosis
- Interventions for psychosis in adolescents
- Interventions to encourage uptake of cancer screening for people with severe mental illness
- Interventions to reduce weight gain in schizophrenia
- Lamotrigine for schizophrenia
- Length of hospitalisation for people with severe mental illness
- Levomepromazine for schizophrenia
- Life skills programmes for chronic mental illnesses
- Lithium for schizophrenia
- Long-acting aripiprazole (depot) versus placebo for schizophrenia
- Loxapine for schizophrenia
- Lurasidone versus typical antipsychotics for schizophrenia
- Magnetic seizure therapy for people with schizophrenia
- Maintenance treatment with antipsychotic drugs for schizophrenia
- Management of sexual dysfunction due to antipsychotic drug therapy
- Memantine for schizophrenia
- Meta-cognitive training for schizophrenia
- Mirtazapine adjunct for people with schizophrenia
- Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
- Modafinil for people with schizophrenia or related disorders
- Molindone for schizophrenia and severe mental illness
- Monetary incentives for schizophrenia
- Mood stabilisers for schizoaffective disorder
- Morita therapy for schizophrenia
- Mother and baby units for schizophrenia
- Music therapy for people with schizophrenia and schizophrenia-like disorders
- New generation antipsychotics for first episode schizophrenia
- Newer atypical antipsychotic medication versus clozapine for schizophrenia
- Nicotine for schizophrenia
- Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia
- Non-clozapine antipsychotic combinations for treatment-resistant schizophrenia
- Nutritional interventions for early psychosis: a systematic review and network meta-analysis
- Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia
- Oestrogen (adjunct) versus placebo for women with schizophrenia
- Olanzapine depot for schizophrenia
- Olanzapine dose for people with schizophrenia
- Olanzapine for schizophrenia
- Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
- Olanzapine versus other atypical antipsychotics for schizophrenia
- Olanzapine versus placebo for people with schizophrenia
- Open Dialogue for psychosis or severe mental illness
- Open general medical wards versus specialist psychiatric units for acute psychoses
- Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) for diagnosing schizophrenia in people with psychotic symptoms
- Oral health education (advice and training) for people with serious mental illness
- Oral paliperidone for schizophrenia
- Outcome measures and needs assessment tools for schizophrenia and related disorders
- Paliperidone palmitate for schizophrenia
- Parenting interventions for people with schizophrenia or related serious mental illness
- Peer support for people with schizophrenia or other serious mental illness
- Penfluridol for schizophrenia
- Perazine for schizophrenia
- Pericyazine for schizophrenia
- Perphenazine for schizophrenia
- Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia
- Pharmacological interventions for acute and transient psychotic disorder (ATPD)
- Pharmacological interventions for clozapine-induced hypersalivation
- Pharmacological interventions for clozapine-induced sinus tachycardia
- Pharmacological interventions for prevention of weight gain in people with schizophrenia
- Pharmacological interventions for reducing weight gain in schizophrenia
- Pharmacological interventions for reduction of weight gain in people with schizophrenia
- Pharmacological treatment for antipsychotic-related constipation
- Pharmacological treatments for psychosis-related polydipsia
- Physical health care monitoring for people with serious mental illness
- Pimozide for schizophrenia or related psychoses
- Placebo versus no treatment for people with schizophrenia
- Polyunsaturated fatty acid supplementation for schizophrenia
- Post-incident debriefing for people with schizophrenia after coercive measures
- Problem solving skills for schizophrenia
- Prompts to encourage appointment attendance for people with serious mental illness
- Psychoeducation (brief) for people with serious mental illness
- Psychoeducation for schizophrenia
- Psychoeducation for siblings of people with severe mental illness
- Psychoeducation for the parents of people with severe mental illness
- Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness
- Psychological interventions for psychosis in adolescents
- Psychosocial interventions for people with both severe mental illness and substance misuse
- Psychosocial telemedicine interventions for schizophreniaNew
- Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
- Quetiapine dose for people with schizophrenia
- Quetiapine for schizophrenia
- Quetiapine versus other atypical antipsychotics for schizophrenia
- Quetiapine versus typical antipsychotic medications for schizophrenia
- Rehabilitation programmes for schizophrenia
- Risk assessment for aggressive behaviour in schizophrenia
- Risperidone (depot) for schizophrenia
- Risperidone (oral forms) for people with schizophrenia
- Risperidone dose for schizophrenia
- Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
- Risperidone versus olanzapine for schizophrenia
- Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse
- Risperidone versus other atypical antipsychotics for schizophrenia
- Risperidone versus placebo for schizophrenia
- Risperidone versus typical antipsychotic medication for schizophrenia
- Saffron (adjunct) for people with schizophrenia who have antipsychotic-induced metabolic syndrome
- Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) for diagnosing schizophrenia in children and adolescents with psychotic symptoms
- Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illness
- Seclusion and restraint for people with serious mental illnesses
- Selective noradrenaline reuptake inhibitors for schizophrenia
- Self-help and guided self-help interventions for schizophrenia and related disorders
- Sertindole for schizophrenia
- Sertindole versus other atypical antipsychotics for schizophrenia
- Smoking cessation advice for people with serious mental illness
- Social skills programmes for schizophrenia
- Specialised early intervention teams (extended time) for recent-onset psychosis
- Specialised early intervention teams for recent-onset psychosis
- Sulpiride augmentation for schizophrenia
- Sulpiride for schizophrenia
- Sulpiride versus other antipsychotics for schizophrenia
- Sulpiride versus placebo for schizophrenia
- Supported employment for adults with severe mental illness
- Supported housing for people with severe mental disorders
- Supportive therapy for schizophrenia
- Switching antipsychotic for non response in schizophrenia
- Tai chi for schizophrenia
- Tai Chi plus standard care versus other exercise plus standard care for people with schizophrenia or related disorders
- Testosterone for schizophrenia
- Thioridazine for schizophrenia
- Token economy for schizophrenia
- Training to recognise the early signs of recurrence in schizophrenia
- Transcranial magnetic stimulation (TMS) for schizophrenia
- Transitional discharge interventions for people with serious mental illness
- Treatments for delusional disorder
- Treatments for primary delusional infestation
- Trifluoperazine for schizophrenia
- Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia
- Trifluoperazine versus placebo for schizophrenia
- Twenty-four hour care for schizophrenia
- Typical antipsychotics for psychosis in adolescents
- Unilateral electroconvulsive therapy versus bilateral electroconvulsive therapy for schizophrenia
- User-held personalised information for routine care of people with severe mental illness
- Valproate for schizophrenia
- Vesicular monoamine transporter inhibitors versus placebo for antipsychotic-induced tardive dyskinesia
- Video games for people with schizophrenia
- Virtual reality for treatment compliance for people with serious mental illness
- Vitamin E for antipsychotic-induced tardive dyskinesia
- Vocational rehabilitation for people with severe mental illness
- Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis
- Wendan decoction (Traditional Chinese medicine) for schizophrenia
- Yoga as part of a package of care versus non-standard care for schizophrenia
- Yoga as part of a package of care versus standard care for schizophrenia
- Yoga for schizophrenia
- Yoga versus non-standard care for schizophrenia
- Yoga versus standard care for schizophrenia
- Ziprasidone for schizophrenia and severe mental illness
- Ziprasidone versus other atypical antipsychotics for schizophrenia
- Zotepine for schizophrenia
- Zotepine versus other atypical antipsychotics for schizophrenia
- Zotepine versus placebo for schizophrenia
- Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
- Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
- Zuclopenthixol dihydrochloride for schizophrenia
- Zuclopenthixol versus placebo for schizophrenia
- Preventing type 2 diabetes in adults with mental health conditions in low- and middle-income countries
- Clinical care - by treatment category (359)
- Alternative medicine/ Chinese herbal medicine (7)
- Acupuncture for schizophrenia
- Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia
- Ayurvedic medicine for schizophrenia
- Chinese herbal medicine for schizophrenia
- Ginkgo biloba versus placebo for schizophrenia
- Saffron (adjunct) for people with schizophrenia who have antipsychotic-induced metabolic syndrome
- Wendan decoction (Traditional Chinese medicine) for schizophrenia
- Arts-based therapies (3)
- Assessment (2)
- Care packages & different (named) types of services (21)
- 'As required' medication regimens for seriously mentally ill people in hospital
- Acceptance and Commitment Therapy for schizophrenia and related disorders
- Advance treatment directives for people with severe mental illness
- Collaborative care approaches for people with severe mental illness
- Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality
- Compulsory community and involuntary outpatient treatment for people with severe mental disorders
- Crisis intervention for people with severe mental illnesses
- Early intervention for psychosis
- Interventions for prodromal stage of psychosis
- Illness management and recovery programme for people with severe mental illness
- Implementation of treatment guidelines for specialist mental health care
- Intensive case management for severe mental illness
- Intermittent drug techniques for schizophrenia
- Length of hospitalisation for people with severe mental illness
- Life skills programmes for chronic mental illnesses
- Mother and baby units for schizophrenia
- Open general medical wards versus specialist psychiatric units for acute psychoses
- Self-help and guided self-help interventions for schizophrenia and related disorders
- Social skills programmes for schizophrenia
- Transitional discharge interventions for people with serious mental illness
- Twenty-four hour care for schizophrenia
- ECT/TMS (5)
- Electroconvulsive therapy for schizophrenia
- Electroconvulsive therapy for treatment-resistant schizophrenia
- Transcranial magnetic stimulation (TMS) for schizophrenia
- Unilateral electroconvulsive therapy versus bilateral electroconvulsive therapy for schizophrenia
- Magnetic seizure therapy for people with schizophrenia
- Educative approaches (26)
- Health Professionals (8)
- Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders
- Educational games for mental health professionals
- Implementation of treatment guidelines for specialist mental health care
- Outcome measures and needs assessment tools for schizophrenia and related disorders
- Post-incident debriefing for people with schizophrenia after coercive measures
- Risk assessment for aggressive behaviour in schizophrenia
- Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illness
- Training to recognise the early signs of recurrence in schizophrenia
- Consumers (18)
- Behavioural family interventions versus structural family interventions for people with schizophrenia
- Family intervention (brief) for schizophrenia
- Dietary advice for people with schizophrenia
- Family intervention for schizophrenia
- Family-based interventions versus standard care for people with schizophrenia
- General physical health advice for people with serious mental illness
- HIV prevention advice for people with serious mental illness
- Interventions to encourage uptake of cancer screening for people with severe mental illness
- Oral health education (advice and training) for people with serious mental illness
- Parenting interventions for people with schizophrenia or related serious mental illness
- Information and communication technology in patient education and support for people with schizophrenia
- Physical health care monitoring for people with serious mental illness
- Psychoeducation for schizophrenia
- Psychoeducation for siblings of people with severe mental illness
- Psychoeducation for the parents of people with severe mental illness
- Self-help and guided self-help interventions for schizophrenia and related disorders
- Smoking cessation advice for people with serious mental illness
- Psychoeducation (brief) for people with serious mental illness
- Health Professionals (8)
- Drugs (247)
- Anti-convulsants / Convulsants (3)
- Amino acids, hormones, enzymes, oils and nutritional agents (11)
- Acetylcholinesterase inhibitors for schizophrenia
- Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia
- Antiglucocorticoid and related treatments for psychosis
- Antioxidant treatments for schizophrenia
- Estrogen for schizophrenia
- Glutamatergic drugs for schizophrenia
- Oestrogen (adjunct) versus placebo for women with schizophrenia
- Polyunsaturated fatty acid supplementation for schizophrenia
- Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
- Testosterone for schizophrenia
- Vitamin E for antipsychotic-induced tardive dyskinesia
- Anti-depressants (9)
- Allopurinol and related drugs for schizophrenia
- Amphetamines for schizophrenia
- Antidepressants for people with both schizophrenia and depression
- Antidepressants for the negative symptoms of schizophrenia
- Chlorpromazine versus lithium for people with schizophrenia
- Lithium for schizophrenia
- Mirtazapine adjunct for people with schizophrenia
- Mood stabilisers for schizoaffective disorder
- Selective noradrenaline reuptake inhibitors for schizophrenia
- Anti-psychotics (182)
- Acetophenazine (1)
- Amisulpiride (2)
- Aripiprazole (13)
- Aripiprazole for neuroleptic induced hyperprolactinaemia
- Aripiprazole for schizophrenia
- Aripiprazole versus brexpiprazole for people with schizophrenia
- Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus other atypical antipsychotics for schizophrenia
- Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus placebo for schizophrenia
- Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses
- Aripiprazole versus typical antipsychotic drugs for schizophrenia
- Aripiprazole versus ziprasidone for schizophrenia
- Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)
- Long-acting aripiprazole (depot) versus placebo for schizophrenia
- Asenapine (2)
- Benperidol (1)
- Bifeprunox (1)
- Blonanserin (1)
- Brexpiprazole (2)
- Bromperidol (1)
- Cariprazine (1)
- Chlorpromazine (15)
- Acetophenazine versus chlorpromazine for schizophrenia
- Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses
- Cessation of medication for people with schizophrenia already stable on chlorpromazine
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
- Chlorpromazine dose for people with schizophrenia
- Chlorpromazine for psychosis induced aggression or agitation
- Chlorpromazine versus lithium for people with schizophrenia
- Chlorpromazine versus metiapine for schizophrenia
- Chlorpromazine versus penfluridol for schizophrenia
- Chlorpromazine versus piperacetazine for schizophrenia
- Chlorpromazine versus placebo for schizophrenia
- Chlorpromazine versus reserpine for schizophrenia
- Chlorpromazine versus thiothixene for people with schizophrenia
- Chlorpromazine versus clotiapine for schizophrenia
- Haloperidol versus chlorpromazine for schizophrenia
- Clotiapine (2)
- Clozapine (13)
- Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia
- Clozapine (generic versus branded) for people with schizophrenia
- Clozapine augmentation for treatment-resistant schizoaffective disorder
- Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
- Clozapine dose for schizophrenia
- Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia
- Clozapine versus olanzapine for people with schizophrenia
- Clozapine versus other atypical antipsychotics for schizophrenia
- Clozapine versus quetiapine for people with schizophrenia
- Clozapine versus risperidone for people with schizophrenia
- Clozapine versus typical neuroleptic medication for schizophrenia
- Pharmacological interventions for clozapine-induced hypersalivation
- Newer atypical antipsychotic medication versus clozapine for schizophrenia
- Droperidol (1)
- Flupenthixol (2)
- Fluphenazine (6)
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
- Fluphenazine decanoate (depot) and enanthate for schizophrenia
- Fluphenazine (dose) for people with schizophrenia
- Fluphenazine decanoate (timing of administration) for people with schizophrenia
- Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia
- Fluphenazine (oral) versus placebo for schizophrenia
- Fluspirilene (1)
- General (26)
- Antipsychotic medication for childhood-onset schizophrenia
- Antipsychotic medication for elderly people with schizophrenia
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Antipsychotics for people with persistent negative symptoms of schizophrenia
- Aripiprazole versus other atypical antipsychotics for schizophrenia
- Aripiprazole versus typical antipsychotic drugs for schizophrenia
- Asenapine versus other atypical antipsychotics for schizophrenia
- Atypical antipsychotics for people with both schizophrenia and depression
- Benperidol for schizophrenia
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
- Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
- Clozapine versus other atypical antipsychotics for schizophrenia
- Clozapine versus typical neuroleptic medication for schizophrenia
- Antipsychotic combinations for schizophrenia
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
- Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
- Lurasidone versus typical antipsychotics for schizophrenia
- Maintenance treatment with antipsychotic drugs for schizophrenia
- Olanzapine for schizophrenia
- Olanzapine versus other atypical antipsychotics for schizophrenia
- Pharmacological interventions for acute and transient psychotic disorder (ATPD)
- Quetiapine for schizophrenia
- Risperidone versus other atypical antipsychotics for schizophrenia
- Risperidone versus typical antipsychotic medication for schizophrenia
- Haloperidol (14)
- Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses
- Depot haloperidol decanoate for schizophrenia
- Haloperidol (route of administration) for people with schizophrenia
- Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
- Haloperidol dose for the acute phase of schizophrenia
- Haloperidol for long-term aggression in psychosis
- Haloperidol plus promethazine for psychosis-induced aggression
- Haloperidol versus chlorpromazine for schizophrenia
- Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
- Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia
- Haloperidol versus olanzapine for people with schizophrenia
- Haloperidol versus placebo for schizophrenia
- Haloperidol versus risperidone for schizophrenia
- Haloperidol discontinuation for people with schizophrenia
- Iloperidone (1)
- Levomepromazine (1)
- Long-acting (10)
- Bromperidol decanoate (depot) for schizophrenia
- Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
- Fluphenazine decanoate (depot) and enanthate for schizophrenia
- Depot fluspirilene for schizophrenia
- Depot haloperidol decanoate for schizophrenia
- Depot perphenazine decanoate and enanthate for schizophrenia
- Depot pipotiazine palmitate and undecylenate for schizophrenia
- Long-acting aripiprazole (depot) versus placebo for schizophrenia
- Risperidone (depot) for schizophrenia
- Olanzapine depot for schizophrenia
- Loxapine (1)
- Lurasidone (1)
- Methotrimeprazine (0)
- Metiapine (1)
- Modafinil (1)
- Molindone (1)
- Olanzapine (8)
- Clozapine versus olanzapine for people with schizophrenia
- Olanzapine depot for schizophrenia
- Olanzapine dose for people with schizophrenia
- Olanzapine for schizophrenia
- Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
- Olanzapine versus other atypical antipsychotics for schizophrenia
- Olanzapine versus placebo for people with schizophrenia
- Risperidone versus olanzapine for schizophrenia
- Palperidone (2)
- Penfluridol (2)
- Perazine (1)
- Pericyazine (1)
- Perphenazine (4)
- Pimozide (1)
- Piperacetazine (1)
- Pipotiazine (1)
- Quetiapine (5)
- Risperidone (12)
- Blonanserin versus risperidone for schizophrenia
- Clozapine versus risperidone for people with schizophrenia
- Haloperidol versus risperidone for schizophrenia
- Risperidone (depot) for schizophrenia
- Risperidone (oral forms) for people with schizophrenia
- Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
- Risperidone dose for schizophrenia
- Risperidone versus olanzapine for schizophrenia
- Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse
- Risperidone versus other atypical antipsychotics for schizophrenia
- Risperidone versus placebo for schizophrenia
- Risperidone versus typical antipsychotic medication for schizophrenia
- Sertindole (2)
- Sulpiride (5)
- Thioridazine (1)
- Thiothixene (1)
- Trifluoperazine (3)
- Ziprasidone (3)
- Zotepine (3)
- Zuclopenthixol (4)
- Anti-movement disorders (8)
- Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia
- Anticholinergics for neuroleptic-induced acute akathisia
- Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesia
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Calcium channel blockers for antipsychotic-induced tardive dyskinesia
- Cholinergic medication for antipsychotic-induced tardive dyskinesia
- Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia
- Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
- Anti-inflammatory (3)
- Calcium channel blockers (1)
- Anticholinergics, beta-blockers, benzodiazepines (11)
- Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms
- Anticholinergic medication for antipsychotic-induced tardive dyskinesia
- Anticholinergics (various) for neuroleptic-induced parkinsonism
- Anticholinergics for neuroleptic-induced acute akathisia
- Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesia
- Anticholinergics versus placebo for neuroleptic-induced parkinsonism
- Benzodiazepines for psychosis-induced aggression or agitation
- Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses
- Benzodiazepines for schizophrenia
- Beta-blocker supplementation of standard drug treatment for schizophrenia
- Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia
- Central nervous system stimulants (4)
- Dose (12)
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Chlorpromazine dose for people with schizophrenia
- Clozapine dose for schizophrenia
- Fluphenazine (dose) for people with schizophrenia
- Haloperidol dose for the acute phase of schizophrenia
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
- Increasing antipsychotic dose for non response in schizophrenia
- Olanzapine dose for people with schizophrenia
- Quetiapine dose for people with schizophrenia
- Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
- Risperidone dose for schizophrenia
- Lipid modifying agents (0)
- Other substances (3)
- ICT (2)
- Physical activity (13)
- Dance therapy for schizophrenia
- Distraction techniques for schizophrenia
- Drama therapy for schizophrenia or schizophrenia-like illnesses
- Exercise therapy for schizophrenia
- Horticultural therapy for schizophrenia
- Intercessory prayer for the alleviation of ill health
- Tai chi for schizophrenia
- Tai Chi plus standard care versus other exercise plus standard care for people with schizophrenia or related disorders
- Yoga as part of a package of care versus standard care for schizophrenia
- Yoga as part of a package of care versus non-standard care for schizophrenia
- Yoga for schizophrenia
- Yoga versus non-standard care for schizophrenia
- Yoga versus standard care for schizophrenia
- Psychological therapies (20)
- Acceptance and Commitment Therapy for schizophrenia and related disorders
- Cognitive behavioural therapy (brief versus standard duration) for schizophrenia
- Cognitive behaviour therapy versus specific pharmacological treatments for schizophrenia
- Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosisNew
- Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
- Cognitive behavioural therapy without medication for schizophreniaNew
- Cognitive rehabilitation for people with schizophrenia and related conditions
- Compliance therapy for schizophrenia
- Computer-based Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders
- Cognitive behavioural therapy (group) for schizophrenia
- Hypnosis for schizophrenia
- Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness
- Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia
- Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia
- Morita therapy for schizophrenia
- Open Dialogue for psychosis or severe mental illness
- Parenting interventions for people with schizophrenia or related serious mental illness
- Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness
- Psychosocial interventions for people with both severe mental illness and substance misuse
- Psychosocial telemedicine interventions for schizophreniaNew
- Life and skills training (13)
- Avatar Therapy for people with schizophrenia or related disorders
- Communication skills training for mental health professionals working with people with severe mental illness
- Distraction techniques for schizophrenia
- Life skills programmes for chronic mental illnesses
- Monetary incentives for schizophrenia
- Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia
- Peer support for people with schizophrenia or other serious mental illness
- Problem solving skills for schizophrenia
- Self-help and guided self-help interventions for schizophrenia and related disorders
- Social skills programmes for schizophrenia
- Supported employment for adults with severe mental illness
- Supportive therapy for schizophrenia
- Token economy for schizophrenia
- Alternative medicine/ Chinese herbal medicine (7)
- Clinical care - by specific additional problem (65)
- Adverse effects/events (33)
- Movement disorders (18)
- Catatonia (1)
- Parkinsonism (4)
- Tardive Dyskinesia (13)
- Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms
- Anticholinergic medication for antipsychotic-induced tardive dyskinesia
- Anticholinergics for neuroleptic-induced parkinsonism and tardive dyskinesia
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
- Benzodiazepines for antipsychotic-induced tardive dyskinesia
- Calcium channel blockers for antipsychotic-induced tardive dyskinesia
- Cholinergic medication for antipsychotic-induced tardive dyskinesia
- Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia
- Miscellaneous treatments for antipsychotic-induced tardive dyskinesia
- Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia
- Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia
- Vesicular monoamine transporter inhibitors versus placebo for antipsychotic-induced tardive dyskinesia
- Vitamin E for antipsychotic-induced tardive dyskinesia
- Polydipsia (1)
- Other (7)
- Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia
- Aripiprazole for neuroleptic induced hyperprolactinaemia
- Beta-blocker supplementation of standard drug treatment for schizophrenia
- Pharmacological treatment for antipsychotic-related constipation
- Interventions for antipsychotic-induced amenorrhoea
- Pharmacological interventions for clozapine-induced hypersalivation
- Pharmacological interventions for clozapine-induced sinus tachycardia
- Weight gain (7)
- Behavioural interventions for reducing weight gain in schizophrenia
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
- Pharmacological interventions for prevention of weight gain in people with schizophrenia
- Interventions to reduce weight gain in schizophrenia
- Pharmacological interventions for reducing weight gain in schizophrenia
- Pharmacological interventions for reduction of weight gain in people with schizophrenia
- Saffron (adjunct) for people with schizophrenia who have antipsychotic-induced metabolic syndrome
- Movement disorders (18)
- Psychosis-induced aggression or agitation (14)
- Benzodiazepines for psychosis-induced aggression or agitation
- Chlorpromazine for psychosis induced aggression or agitation
- Clotiapine for acute psychotic illnesses
- Containment strategies for people with serious mental illness
- De-escalation techniques for psychosis-induced aggression or agitation
- Droperidol for psychosis-induced aggression or agitation
- Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
- Haloperidol plus promethazine for psychosis-induced aggression
- Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)
- Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
- Post-incident debriefing for people with schizophrenia after coercive measures
- Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation)
- Seclusion and restraint for people with serious mental illnesses
- Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
- Compliance (3)
- Persistent aggression (6)
- Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia
- Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia
- Containment strategies for people with serious mental illness
- Haloperidol for long-term aggression in psychosis
- Post-incident debriefing for people with schizophrenia after coercive measures
- Seclusion and restraint for people with serious mental illnesses
- Treatment resistant (9)
- Antipsychotics for people with persistent negative symptoms of schizophrenia
- Clozapine augmentation for treatment-resistant schizoaffective disorder
- Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
- Electroconvulsive therapy for treatment-resistant schizophrenia
- Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
- Increasing antipsychotic dose for non response in schizophrenia
- Lamotrigine for schizophrenia
- Non-clozapine antipsychotic combinations for treatment-resistant schizophrenia
- Switching antipsychotic for non response in schizophrenia
- Adverse effects/events (33)
- Clinical care - by state/stage of illness (16)
- Early (6)
- Antipsychotic medication for early episode schizophrenia
- Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosisNew
- Early intervention for psychosis
- Specialised early intervention teams (extended time) for recent-onset psychosis
- Specialised early intervention teams for recent-onset psychosis
- New generation antipsychotics for first episode schizophrenia
- Acute (4)
- Chronic (5)
- Cessation of medication for people with schizophrenia already stable on chlorpromazine
- Haloperidol for long-term aggression in psychosis
- Life skills programmes for chronic mental illnesses
- Maintenance treatment with antipsychotic drugs for schizophrenia
- Preventing type 2 diabetes in adults with mental health conditions in low- and middle-income countries
- Prodromal (1)
- Early (6)
- Clinical care - by stage of life (8)
- Adolescent (2)
- Children (1)
- Elderly (0)
- Late onset (2)
- Child bearing age (3)
- Clinical care - by specific diagnosis (27)
- Acute and transient psychotic disorder (ATPD) (1)
- Catatonic schizophrenia (2)
- Delusional disorder (2)
- Dual diagnosis - affective disorder (1)
- Dual diagnosis - learning disability (1)
- Dual diagnosis - substance abuse (1)
- Psychosis (15)
- Antiglucocorticoid and related treatments for psychosis
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
- Benzodiazepines for psychosis-induced aggression or agitation
- Chlorpromazine for psychosis induced aggression or agitation
- Clotiapine for acute psychotic illnesses
- Cognitive behavioural therapy without medication for schizophreniaNew
- De-escalation techniques for psychosis-induced aggression or agitation
- Droperidol for psychosis-induced aggression or agitation
- Early intervention for psychosis
- Interventions for prodromal stage of psychosis
- Haloperidol for long-term aggression in psychosis
- Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)
- Open general medical wards versus specialist psychiatric units for acute psychoses
- Psychological interventions for psychosis in adolescents
- Typical antipsychotics for psychosis in adolescents
- Schizoaffective disorder (2)
- Schizophreniform disorder (0)
- Treatment resistant (2)
- Diagnostic tests (4)
- Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis
- First rank symptoms for schizophrenia
- Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) for diagnosing schizophrenia in people with psychotic symptoms
- Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) for diagnosing schizophrenia in children and adolescents with psychotic symptoms